Introduction
============

Adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) for early-stage breast cancer patients of old age is controversial. Elderly patients have a high prevalence of comorbidity \[[@b1-crt-2018-163]\], and the rate of other-cause mortality increases with age \[[@b2-crt-2018-163]\]. Treatment-induced morbidity is also a considerable factor \[[@b3-crt-2018-163]\]. Early-stage breast cancer is associated with a relatively low mortality rate, and old age itself can be considered a low risk factor compared with young age in breast cancer patients \[[@b4-crt-2018-163]\]. Therefore, reduced treatments may not decrease the survival rate in elderly patients compared with conventional treatments \[[@b5-crt-2018-163]\]. Two randomized controlled trials (Cancer and Leukemia Group B \[CALGB\] 9343 \[[@b6-crt-2018-163]\] and PRIME II \[[@b7-crt-2018-163]\]) demonstrated no overall survival benefit from adjuvant RT in elderly patients with early-stage breast cancer after BCS.

In contrast, it appears that RT reduces local recurrence irrespective of age \[[@b8-crt-2018-163]\]. Many studies have shown that reduced treatments for elderly breast cancer patients significantly decreased the cancer-specific survival (CSS) rate \[[@b2-crt-2018-163],[@b9-crt-2018-163],[@b10-crt-2018-163]\].

The National Comprehensive Cancer Network recommends selective administration of RT for women ≥ 70 years of age with stage I breast cancer \[[@b11-crt-2018-163]\], while the International Society of Geriatric Oncology, European Society of Breast Cancer Specialists \[[@b12-crt-2018-163]\], and the 14th St. Gallen International Breast Cancer conference \[[@b13-crt-2018-163]\] recommend that RT should not be omitted regardless of age.

In clinical practice, there is a prevalent demand to reduce treatments in elderly patients \[[@b14-crt-2018-163],[@b15-crt-2018-163]\]. These efforts to avoid over-treatment, however, may lead to under-treatment of elderly patients who can achieve survival benefits from conventional treatments. Therefore, a precise selection of the patient groups for RT is mandatory.

Accumulating evidence has indicated that the molecular subtype of breast cancer is a significant prognostic factor \[[@b16-crt-2018-163]\]. Especially, hormone receptor (HR)‒positive breast cancer has a good prognosis compared with HR-negative cancer \[[@b17-crt-2018-163]\]. In addition, other prognostic factors, such as tumor size and grade, may also influence treatment outcomes. An optimal cut-off age to dichotomize patients into young and old groups is also needed.

In this study, a contemporary population-based cohort was examined to evaluate the effect of omitting adjuvant RT from the treatment of HR-positive early-stage breast cancer in elderly patients of various age groups by comparing CSS rates between no-RT and RT groups.

Materials and Methods
=====================

1. Study population
-------------------

A list of patients was retrieved from the Surveillance, Epidemiology, and End Results (SEER) 18 database using the case listing option of the survival session of the SEER\*Stat software program. Since the SEER data consists of de-identified data, this study was exempt from the Institutional Review Boards approval process.

The inclusion criteria were as follows: (1) pathologically confirmed breast cancer as the first primary cancer, (2) female, (3) aged 50 ≥ years, (4) T1N0 stage, (5) HR (estrogen receptor or progesterone receptor)--positive cancer, (6) diagnosed from 2004 to 2014, (7) received BCS (surgery code 20-24), (8) received at least one regional lymph node examinations, (9) having information regarding adjuvant RT (no/unknown, refused, or beam radiation after surgery), tumor grade, tumor size, and number of examined lymph nodes. Patients who were diagnosed by a death certificate only or autopsy only or patients without survival information were excluded.

In the SEER 18 database, four tumor grade scales were used: grade 1, well-differentiated; grade 2, moderately differentiated; grade 3, poorly differentiated; and grade 4, undifferentiated or anaplastic. The Nottingham or Bloom--Richardson (BR) grade (1-3) has been additionally reported for breast cancer since 2010, and the BR grade from 1 to 3 was well matched with the previously reported tumor grade from 1 to 3, respectively. As grade 4 was defined as undifferentiated or anaplastic differentiation, it was considered a poor prognosis.

2. Propensity score matching
----------------------------

Before propensity score matching, the no-RT and RT groups were compared using Pearson's chi-square test. One-to-one (1:1) propensity score matching between the no-RT and RT groups was conducted using a nearest neighbor algorithm. The matched variables were age, race, year of diagnosis, tumor grade, histology, tumor size, number of examined lymph nodes, chemotherapy (yes or no), insurance, and marital status.

After propensity score matching, a comparison of the variable distributions between the no-RT and RT groups was performed again using Pearson's chi-square test to evaluate the effectiveness of propensity score matching.

3. Univariate and multivariate analyses
---------------------------------------

After propensity score matching, univariate analysis of the effect of each variable on the 10-year CSS rate was performed using the Kaplan-Meier survival estimate followed by logrank test. Variables that were statistically significant with a p-value of \< 0.05 in the univariate analysis were then incorporated into a multivariate analysis. Multivariate analysis using the Cox proportional hazards model was performed to generate an adjusted hazard ratio (aHR) and a p-value for each variable. The variables with a notably high or low aHR and with statistical and clinical significances were selected and used to stratify risk groups.

4. Comparison of 10-year CSS rates between the no-RT and RT groups
------------------------------------------------------------------

In each classified risk group, the 10-year CSS rates were calculated and then compared between the no-RT and RT groups using the Kaplan-Meier method followed by log-rank test. A Cox proportional hazards model was used for multivariate analysis, incorporating all variables, to calculate the aHR for RT in each risk group.

5. Statistical analysis
-----------------------

The CSS was defined as the time from diagnosis to death attributable to this breast cancer. Individuals who were alive or dead due to other cause were considered to be censored. The SEER database offers the SEER cause-specific death classification data.

The R software (ver. 3.3.3, <http://www.r-project.org/>) package 'MatchIt' was used to perform propensity score matching, and packages 'survminer' and 'survival' were used to generate plots comparing the 10-year CSS rate between the no-RT and RT groups in each risk group. All other statistical calculations were performed using Stata software (Stata/MP ver. 14.2, StataCorp., College Station, TX).

6. Ethical statement
--------------------

The Institutional Review Board (IRB) deemed this study using de-identified data to be exempt from IRB approval. Informed consent was not required because of the retrospective nature of the study. All procedures performed in studies were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Results
=======

1. Patient characteristics prior to propensity score matching
-------------------------------------------------------------

All patients were HR-positive stage I breast cancer patients treated with BCS. The numbers of patients in the no-RT and RT groups were 18,586 (20.3%) and 72,863 (79.7%), respectively ([Table 1](#t1-crt-2018-163){ref-type="table"}). Patients who were not treated with adjuvant RT were older than those treated with RT. The numbers of patients ≥ 70 years of age were 9,470 (50.9%) and 20,654 (28.4%) in the no-RT and RT groups, respectively (p \< 0.001). There were 7,462 (40.1%), 8,503 (45.7%), 2,567 (13.8%), and 54 (0.3%) patients in the no-RT group and 28,294 (38.8%), 34,728 (47.7%), 9,691 (13.3%), and 150 (0.2%) in the RT group with tumor grades 1, 2, 3, and 4, respectively (p \< 0.001). The majority of patients received 1-4 lymph node examinations in the no-RT (81.3%) and RT groups (82.3%); slightly more patients received ≥ 10 lymph node examinations in the no-RT group than the RT group (5.3% vs. 4.7%). More patients received chemotherapy in the RT group than in the no-RT group (9.5% vs. 13.1%).

2. Patient characteristics after propensity score matching
----------------------------------------------------------

Propensity score matching (1:1) between the no-RT and RT groups was performed. After matching, the numbers of patients in the no-RT and RT groups were the same (18,586 vs. 18,586), and only the variables race and insurance status showed a significantly difference between the groups. There were 5,913 (31.8%) and 6,023 (32.4%) patients aged 70-79 years and 3,557 (19.1%) and 3,490 (18.8%) patients aged ≥ 80 years in the no-RT and RT groups, respectively (p=0.557) ([Table 1](#t1-crt-2018-163){ref-type="table"}).

3. Univariate and multivariate analyses
---------------------------------------

After propensity score matching, univariate analysis of the CSS rate was performed. Except for the year of diagnosis and number of examined lymph nodes, all variables showed significant prognostic power with p \< 0.05. Especially, old age, high tumor grade, tumor size \> 10 mm, and no-RT indicated a significantly poor prognosis ([Table 2](#t2-crt-2018-163){ref-type="table"}).

Multivariate analysis was performed after incorporating age, race, tumor grade, histology, tumor size, chemotherapy, RT, insurance, and marital status. As a result, old age (aHR for 60-69 years compared with 50-59 years, 1.324; p=0.028; aHR for 70-79 years, 2.105; p \< 0.001; aHR for ≥ 80 years, 3.647; p \< 0.001), high grade (aHR for grade 3-4, 2.212; p \< 0.001), histologies which are neither invasive ductal carcinoma (IDC) nor invasive lobular carcinoma (ILC) (aHR for other histology compared with IDC, 0.688; p \< 0.001), and tumor size \> 10 mm (aHR for 11-20 mm, 1.520; p \< 0.001) were significantly correlated with a poor prognosis.

The worse CSS in older age may be related to the possibility that extremely elderly patients did not receive active treatments when recurrences occurred. The number of patients and the 10-year CSS rate for each histology after propensity score matching were as follows: IDC (n=27,391; 10-year CSS, 94.9%), ILC (n=2,526, 94.7%), infiltrating duct and lobular carcinoma (n=2,548, 96.1%), infiltrating duct mixed other types of carcinoma (n=1,538, 96.2%), mucinous adenocarcinoma (n=1,398, 97.4%), and tubular adenocarcinoma (n=682, 97.5%). The numbers of patients in the other histologies were less than 200 per histology. The survivals of major histologies other than pure IDC and ILC were favorable. Especially the good prognoses of mucinous adenocarcinoma and tubular adenocarcinoma seemed to be the reasons of the significantly favorable CSS in the histologies except IDC and ILC.

Patients treated with RT showed a significantly favorable prognosis (aHR, 0.622; p \< 0.001), while patients treated with chemotherapy were correlated with a significantly poor prognosis (aHR, 1.566; p \< 0.001). A higher proportion of patients who received chemotherapy had a tumor grade of 3-4 (1,498 of 3,518 \[42.6%\]) compared with those who did not receive chemotherapy (3,780 of 33,654 \[11.2%\]), suggesting that a high tumor grade may influence the adverse effect of chemotherapy on the CSS rate.

4. Comparison of 10-year CSS rates between the no-RT and RT groups
------------------------------------------------------------------

The 10-year CSS rates were compared between the no-RT and RT groups in each risk group stratified by significantly prognostic variables in a multivariate analysis (age, tumor grade, and tumor size) ([Table 3](#t3-crt-2018-163){ref-type="table"}). Tumor size (1-10 mm vs. 11-20 mm) and tumor grade (1-2 vs. 3-4) were used to generate four (2×2) risk groups. The CSS rate was compared between the no-RT and RT groups in each risk group according to age group (≥ 50, ≥ 55, ≥ 60, ≥ 65, ≥ 70, ≥ 75, ≥ 80, and ≥ 85 years).

In the risk group with a tumor size of 1-10 mm and tumor grade of 1-2, no significant difference in CSS was observed between the no-RT and RT groups in any of the age groups. The 10-year CSS rates were 97.2% and 96.8% in the no-RT and RT groups, respectively, among patients ≥ 50 years of age (p=0.349) ([Fig. 1](#f1-crt-2018-163){ref-type="fig"}). In a multivariate analysis incorporating adjuvant RT, age, race, year of diagnosis, histology, number of examined lymph nodes, chemotherapy, insurance, and marital status, the aHR for RT was not statistically significant regardless of age (age ≥ 50 years: aHR, 0.862; 95% confidence interval \[CI\], 0.646 to 1.150; p=0.312) ([Figs. 1](#f1-crt-2018-163){ref-type="fig"} and [2](#f2-crt-2018-163){ref-type="fig"}).

As shown in [Figs. 1](#f1-crt-2018-163){ref-type="fig"} and [2](#f2-crt-2018-163){ref-type="fig"}, the declining patient number over time reflects death from any causes. The number of patients in the no-RT group decreased more rapidly compared to that in the RT group even in the risk group with a tumor size of 1-10 mm and tumor grade of 1-2, suggesting that patients with high co-morbidity may have received less adjuvant RT. However, there was no difference in breast cancer-related mortality (CSS) in the risk group with a tumor size of 1-10 mm and tumor grade of 1-2.

In the patients aged ≥ 50 years with a tumor size of 11-20 mm and tumor grade of 1-2, the 10-year CSS rates were 93.4% and 95.9% in the no-RT and RT groups, respectively (p \< 0.001). This favorable prognosis in the RT group was seen in every age group evaluated. Multivariate analyses demonstrated that RT increased the CSS rate significantly after adjusting for other prognostic variables (age ≥ 50 years: aHR for RT, 0.591; 95% CI, 0.468 to 0.746; p \< 0.001).

In the patients with a tumor size of 1-10 mm and tumor grade of 3-4, the 10-year CSS rates were 90.9% and 96.4% in the no-RT and RT groups, respectively (p=0.005). Although RT did not show a significant survival benefit for patients of very old age in the multivariate analysis (≥ 80 and ≥ 85 years), these CSS rates were considerably different between the no-RT and RT groups, with a low aHR (age ≥ 80 years: aHR of RT, 0.337; 95% CI, 0.094 to 1.201; p=0.093), suggesting that the relatively small sample size of very old age patients may have contributed to the lack of statistical significance.

In patients with a tumor size of 11-20 mm and tumor grade of 3-4, a significant improvement in the 10-year CSS rate by RT was observed for patients aged ≥ 50 years (88.5% and 93.8% in the no-RT and RT groups, respectively; p \< 0.001). According to multivariate analysis, RT increased CSS significantly in all age groups (age ≥ 50 years: aHR for RT, 0.524; 95% CI, 0.373 to 0.735; p \< 0.001) ([Figs. 1](#f1-crt-2018-163){ref-type="fig"} and [2](#f2-crt-2018-163){ref-type="fig"}).

Discussion
==========

Our study demonstrated that omitting RT in the treatment of patients aged ≥ 50 years with HR-positive early-stage breast cancer (T1N0) after BCS did not decrease the 10-year CSS rate when both conditions of tumor size ≤ 10 mm and low tumor grade (1-2) were satisfied. RT significantly increased the 10-year CSS rate of patients with a tumor size \> 10 mm or a high tumor grade (3-4) irrespective of age, suggesting that omitting RT may be a reasonable option for elderly patients, but only in those with a tumor size ≤ 10 mm and tumor grade ≤ 2.

Adjuvant RT after BCS has long been a dogma, even for elderly patients, as a significant 10-year recurrence-free survival benefit from RT has been reported in all age groups \[[@b18-crt-2018-163]\]. However, as the treatment outcomes in breast cancer have improved \[[@b19-crt-2018-163]\], the possibility of omitting RT in elderly patients is being examined with caution.

Based on the prognostic value of the molecular subtype even in early-stage breast cancer \[[@b20-crt-2018-163]-[@b22-crt-2018-163]\], two randomized trials have evaluated RT in elderly patients with HR-positive, early-stage breast cancer (CALGB 9343 \[[@b6-crt-2018-163]\] and PRIME II \[[@b7-crt-2018-163]\]). The patients were aged ≥ 70 years and ≥ 65 years in the CALGB 9343 and PRIME II trials, respectively. In these trials, RT significantly decreased the 10-year locoregional recurrence rate from 10% to 2% and the 5-year ipsilateral breast tumor recurrence rate from 4.1% to 1.3%. Although RT decreased the locoregional recurrence rate in both trials, this effect did not lead to an overall survival benefit in elderly patients with limited life expectancies in either trial, suggesting that the omission of RT can be considered for select patients. However, the selection of such patients in clinical practice may require stricter risk assessments to avoid undertreatment of elderly patients.

Moreover, the tumor grade was not reported in the CALGB 9343, and the number of patients with tumor grade 3 was limited in PRIME II (23 (3.5%) in the no-RT group and 54 (2.0%) in the RT group). Tumor grade has prognostic value, even in the molecular era, with accumulating evidence showing that grade is strongly related to tumor behavior \[[@b23-crt-2018-163]\].

Considering the prognostic importance of tumor grade, the American Joint Committee on Cancer staging system, eighth edition, incorporated tumor grade to refine prognosis \[[@b24-crt-2018-163]\]. For HR-positive early-stage breast cancer, which has limited prognostic factors (tumor size ≤ 20 mm, no lymph node involvement, and HR positivity), the importance of the tumor grade as a prognostic factor may increase. In our study, tumor grade was identified as a significant prognostic factor for HR-positive early-stage breast cancer patients, with one of the highest aHRs (2.212) in the multivariate analysis. Therefore, prognostic analysis according to tumor grade would be useful for determining whether to administer RT to elderly patients.

Our study also demonstrated that tumor size is another significant factor determining a CSS benefit from RT; RT increased CSS in patients with a tumor size \> 10 mm (T1c) but not in those with a tumor size ≤ 10 mm (T1a or T1b) and a low tumor grade (1-2). A larger tumor size implies a higher tumor burden and insufficiently wide excision, resulting in prognostic differences, even among early-stage breast cancer patients with a small tumor size \[[@b25-crt-2018-163]\]. Several studies have demonstrated that tumor size may not be a main determinant of prognosis for early-stage breast cancer patients \[[@b26-crt-2018-163],[@b27-crt-2018-163]\]. However, in a confined molecular subtype setting (HR positivity), tumor size appears to be a significant prognosticator, especially when deciding whether to omit adjuvant RT, which is a conventional treatment administered after BCS. Therefore, in HR-positive early-stage breast cancer with a tumor size ≤ 20 mm, omitting RT may cause adverse effects unless the tumor size is substantially small (e.g., ≤ 10 mm).

Studies on elderly breast cancer patients used various cutoffs to define old age, including \> 50 years \[[@b28-crt-2018-163]\], 55 years \[[@b14-crt-2018-163]\], 65 years \[[@b7-crt-2018-163]-[@b9-crt-2018-163]\], or 70 years \[[@b6-crt-2018-163]\]. In our study, no cut-off age was identified that significantly divided the treatment outcomes. Every age group showed similar results in terms of RT effects. One study demonstrated that breast cancer patients aged ≥ 80 years received less aggressive treatment and had higher cancer-specific mortality compared with younger patients \[[@b10-crt-2018-163]\]. Therefore, even for very old patients, omitting RT based on age should be avoided unless the life expectancy is obviously short and comorbidities are present, and only low risk groups, according to HR, tumor size, and tumor grade, should consider RT omission as an option.

Hepel and Wazer \[[@b29-crt-2018-163]\] suggested that the omission of RT is an option for patients with a life expectancy \< 5 years or for patients with a low risk of local recurrence or distant metastasis. However, for high-risk patients, such as those with a high tumor grade, lymphovascular invasion, or human epidermal growth factor receptor 2 positivity, RT is strongly recommended. In the same manner, our study supports that HR positivity, tumor grade, and tumor size should be considered in the decision to omit RT in the treatment of elderly patients.

As the SEER 18 database does not provide information on hormone therapy, the effect of hormone therapy could not be evaluated. However, as hormone therapy is a standard treatment for HR-positive breast cancer patients, the majority of HR-positive patients are assumed to receive hormone therapy. Information on local recurrence and distant metastasis was not available. Therefore, the possibility of a decrease in the recurrence-free survival rate without a decrease in the CSS rate in low-risk, early-stage breast cancer indicates that the omission of RT in relatively young patients should be considered with caution. Information on performance status, comorbidities, lymphovascular invasion, surgical margins, human epidermal growth factor receptor 2 status, RT dose, and fraction was also not available.

In conclusion, in elderly patients with HR-positive earlystage breast cancer (T1N0), omitting RT did not decrease the CSS rate of patients with a tumor size ≤ 10 mm and tumor grade ≤ 2, suggesting that omitting RT is a possible treatment option for these patients. For patients with a tumor size \> 10 mm or tumor grade 3-4, RT significantly increased the CSS rate regardless of age. Therefore, even in elderly patients with HR-positive early-stage breast cancer, omitting RT should be considered with caution.
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![Kaplan-Meier estimates of the cancer-specific survival (CSS) rate of patients with hormone receptor‒positive T1N0 breast cancer aged ≥ 50 years according to whether adjuvant radiotherapy (RT) after breast conserving surgery was received or not. (A) Tumor size 1-10 mm and tumor grade 1-2. (B) Tumor size 11-20 mm and tumor grade 1-2. (C) Tumor size 1-10 mm and tumor grade 3-4. (D) Tumor size 11-20 mm and tumor grade 3-4.](crt-2018-163f1){#f1-crt-2018-163}

![Kaplan-Meier estimates of the cancer-specific survival (CSS) rate of patients with hormone receptor‒positive T1N0 breast cancer aged ≥ 65 years according to whether adjuvant radiotherapy (RT) after breast conserving surgery was received or not. (A) Tumor size 1-10 mm and tumor grade 1-2. (B) Tumor size 11-20 mm and tumor grade 1-2. (C) Tumor size 1-10 mm and tumor grade 3-4. (D) Tumor size 11-20 mm and tumor grade 3-4.](crt-2018-163f2){#f2-crt-2018-163}

###### 

Patient characteristics with HR-positive T1N0 breast cancer according to radiotherapy after BCS

  Characteristic            Before PSM      p-value^[a)](#tfn1-crt-2018-163){ref-type="table-fn"}^   After PSM   p-value^[a)](#tfn1-crt-2018-163){ref-type="table-fn"}^                   
  ------------------------- --------------- -------------------------------------------------------- ----------- -------------------------------------------------------- --------------- -------
  **Age (yr)**                                                                                                                                                                            
   50-59                    4,205 (22.6)    23,808 (32.7)                                            \< 0.001    4,205 (22.6)                                             4,147 (22.3)    0.557
   60-69                    4,911 (26.4)    28,401 (39.0)                                                        4,911 (26.4)                                             4,926 (26.5)    
   70-79                    5,913 (31.8)    16,506 (22.7)                                                        5,913 (31.8)                                             6,023 (32.4)    
   ≥ 80                     3,557 (19.1)    4,148 (5.7)                                                          3,557 (19.1)                                             3,490 (18.8)    
  **Race**                                                                                                                                                                                
   White                    15,889 (85.5)   62,249 (85.4)                                            \< 0.001    15,889 (85.5)                                            15,914 (85.6)   0.012
   Black                    1,293 (7.0)     4,885 (6.7)                                                          1,293 (7.0)                                              1,278 (6.9)     
   Other                    1,226 (6.6)     5,442 (7.5)                                                          1,226 (6.6)                                              1,271 (6.8)     
   Unknown                  178 (1.0)       287 (0.4)                                                            178 (1.0)                                                123 (0.7)       
  **Year of diagnosis**                                                                                                                                                                   
   2004-2009                9,105 (49.0)    36,091 (49.5)                                            0.185       9,105 (49.0)                                             9,274 (49.9)    0.080
   2010-2014                9,481 (51.0)    36,772 (50.5)                                                        9,481 (51.0)                                             9,312 (50.1)    
  **Tumor grade**                                                                                                                                                                         
   1-2                      15,965 (85.9)   63,022 (86.5)                                            0.035       15,965 (85.9)                                            15,929 (85.7)   0.593
   3-4                      2,621 (14.1)    9,841 (13.5)                                                         2,621 (14.1)                                             2,657 (14.3)    
  **Histology**                                                                                                                                                                           
   IDC                      13,698 (73.7)   55,115 (75.6)                                            \< 0.001    13,698 (73.7)                                            13,693 (73.7)   0.956
   ILC                      1,256 (6.8)     5,502 (7.6)                                                          1,256 (6.8)                                              1,270 (6.8)     
   Other                    3,632 (19.5)    12,246 (16.8)                                                        3,632 (19.5)                                             3,623 (19.5)    
  **Tumor size (mm)**                                                                                                                                                                     
   1-10                     8,862 (47.7)    35,484 (48.7)                                            0.013       8,862 (47.7)                                             8,772 (47.2)    0.350
   11-20                    9,724 (52.3)    37,379 (51.3)                                                        9,724 (52.3)                                             9,814 (52.8)    
  **No. of examined LNs**                                                                                                                                                                 
   1-4                      15,107 (81.3)   59,993 (82.3)                                            0.001       15,107 (81.3)                                            15,121 (81.4)   0.980
   5-9                      2,500 (13.5)    9,460 (13.0)                                                         2,500 (13.5)                                             2,487 (13.4)    
   ≥ 10                     979 (5.3)       3,410 (4.7)                                                          979 (5.3)                                                978 (5.3)       
  **Chemotherapy**                                                                                                                                                                        
   No/Unknown               16,826 (90.5)   63,288 (86.9)                                            \< 0.001    16,826 (90.5)                                            16,828 (90.5)   0.972
   Yes                      1,760 (9.5)     9,575 (13.1)                                                         1,760 (9.5)                                              1,758 (9.5)     
  **Insurance**                                                                                                                                                                           
   Uninsured                136 (0.7)       469 (0.6)                                                0.369       136 (0.7)                                                98 (0.5)        0.030
   Insured                  13,895 (74.8)   54,393 (74.7)                                                        13,895 (74.8)                                            13,850 (74.5)   
   Unknown                  4,555 (24.5)    18,001 (24.7)                                                        4,555 (24.5)                                             4,638 (25.0)    
  **Marital status**                                                                                                                                                                      
   Married                  9,216 (49.6)    43,970 (60.3)                                            \< 0.001    9,216 (49.6)                                             9,250 (49.8)    0.839
   Other                    8,258 (44.4)    26,260 (36.0)                                                        8,258 (44.4)                                             8,249 (44.4)    
   Unknown                  1,112 (6.0)     2,633 (3.6)                                                          1,112 (6.0)                                              1,087 (5.8)     

Values are presented as number (%). HR, hormone receptor; BCS, breast conserving surgery; PSM, propensity score matching; RT, radiotherapy; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LN, lymph node.

Pearson\'s chi-square test.

###### 

Univariate and multivariate analyses of the CSS rate in HR-positive T1N0 breast cancer after PSM

  Characteristic              Univariate   Multivariate                                        
  --------------------------- ------------ -------------- ---------- ----------- ------------- ----------
  **All**                                                                                      
  **Age (yr)**                                                                                 
   50-59                      96.3         95.3-97.2      \< 0.001   Reference                 
   60-69                      96.4         95.5-97.1                 1.324       1.030-1.701   0.028
   70-79                      95.5         94.6-96.2                 2.105       1.651-2.684   \< 0.001
   ≥ 80                       91.2         89.2-92.8                 3.647       2.835-4.691   \< 0.001
  **Race**                                                                                     
   White                      95.2         94.7-95.7      0.018      Reference                 
   Black                      94.2         92.1-95.8                 1.232       0.935-1.625   0.139
   Other                      96.7         94.0-98.2                 0.692       0.473-1.012   0.058
   Unknown                    96.7         89.6-99.0                 0.900       0.289-2.808   0.857
  **Year of diagnosis**                                                                        
   2004-2009                  98.2         98.0-98.4      0.756                                
   2010-2014                  98.6         98.3-98.9                 NA                        
  **Grade**                                                                                    
   1-2                        95.9         95.3-96.3      \< 0.001   Reference                 
   3-4                        92.1         90.5-93.4                 2.212       1.853-2.640   \< 0.001
  **Histology**                                                                                
   IDC                        94.9         94.3-95.5      0.006      Reference                 
   ILC                        94.7         91.7-96.6                 0.926       0.677-1.267   0.631
   Other                      96.5         95.5-97.3                 0.688       0.557-0.851   0.001
  **Tumor size (mm)**                                                                          
   1-10                       96.7         96.1-97.2      \< 0.001   Reference                 
   11-20                      94.1         93.2-94.8                 1.520       1.291-1.790   \< 0.001
  **No. of examined LNs**                                                                      
   1-4                        95.4         94.8-95.9      0.064                                
   5-9                        94.9         93.4-96.0                 NA                        
   ≥ 10                       94.8         93.0-96.1                                           
  **Chemotherapy**                                                                             
   No/Unknown                 95.4         94.8-95.9      0.004      Reference                 
   Yes                        94.4         92.6-95.7                 1.566       1.226-2.001   \< 0.001
  **Adjuvant radiotherapy**                                                                    
   No/Unknown                 94.4         93.5-95.1      \< 0.001   Reference                 
   Yes                        96.1         95.5-96.7                 0.622       0.533-0.725   \< 0.001
  **Insurance**                                                                                
   Uninsured                  97.8         93.1-99.3      0.020      Reference                 
   Insured                    98.3         98.1-98.5                 0.590       0.219-1.590   0.297
   Unknown                    98.0         97.7-98.3                 0.767       0.284-2.069   0.600
  **Marital status**                                                                           
   Married                    95.8         95.1-96.4      \< 0.001   Reference                 
   Other                      94.6         93.9-95.3                 1.186       1.010-1.393   0.037
   Unknown                    95.7         91.4-97.9                 0.753       0.492-1.153   0.193

CSS, cancer-specific survival; HR, hormone receptor; PSM, propensity score matching; CI, confidence interval; aHR, adjusted hazard ratio; NA, not applicable; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LN, lymph node.

Kaplan-Meier survival estimates compared by log-rank test,

Cox proportional hazards model.

###### 

CSS rate in HR-positive T1N0 breast cancer according to age, size, and grade after PSM

  Age (yr)                             Univariate   Multivariate                                                                           
  ------------------------------------ ------------ -------------- ----------- ------- ------ ----------- ---------- ------- ------------- ----------
  **Tumor size 1-10 mm, grade 1-2**                                                                                                        
   ≥ 50                                8,047        97.2           96.4-97.8   7,915   96.8   95.8-97.6   0.349      0.862   0.646-1.150   0.312
   ≥ 55                                7,361        96.9           96.0-97.6   7,257   96.7   95.6-97.5   0.213      0.825   0.614-1.108   0.201
   ≥ 60                                6,547        96.6           95.5-97.4   6,427   96.7   95.6-97.5   0.177      0.801   0.590-1.088   0.156
   ≥ 65                                5,563        96.3           95.1-97.3   5,375   96.4   95.1-97.4   0.214      0.807   0.585-1.112   0.190
   ≥ 70                                4,472        96.3           95.0-97.3   4,353   96.1   94.5-97.2   0.268      0.819   0.580-1.156   0.256
   ≥ 75                                2,955        95.7           93.7-97.0   2,613   95.0   92.5-96.7   0.392      0.838   0.558-1.258   0.393
   ≥ 80                                1,562        94.2           90.0-96.6   1,400   93.4   88.5-96.2   0.974      0.984   0.581-1.666   0.952
   ≥ 85                                502          93.6           87.0-96.9   289     95.7   90.8-98.0   0.608      0.792   0.312-2.012   0.625
  **Tumor size 11-20 mm, grade 1-2**                                                                                                       
   ≥ 50                                7,918        93.4           91.7-94.7   8,014   95.9   94.8-96.8   \< 0.001   0.591   0.468-0.746   \< 0.001
   ≥ 55                                7,056        92.4           90.5-94.0   7,195   95.8   94.7-96.8   \< 0.001   0.550   0.433-0.699   \< 0.001
   ≥ 60                                6,112        92.7           90.8-94.2   6,223   95.6   94.2-96.7   \< 0.001   0.591   0.468-0.746   \< 0.001
   ≥ 65                                5,141        91.4           88.9-93.3   5,177   95.0   93.3-96.3   \< 0.001   0.543   0.421-0.700   \< 0.001
   ≥ 70                                4,053        90.3           87.4-92.6   4,142   94.9   93.1-96.2   \< 0.001   0.513   0.385-0.685   \< 0.001
   ≥ 75                                2,854        88.7           85.1-91.6   2,662   94.1   91.7-95.8   \< 0.001   0.497   0.359-0.687   \< 0.001
   ≥ 80                                1,659        86.8           80.5-91.2   1,691   92.2   88.2-94.8   0.001      0.527   0.362-0.769   0.001
   ≥ 85                                651          75.4           57.5-86.6   382     87.8   64.0-96.3   0.021      0.477   0.241-0.942   0.033
  **Tumor size 1-10 mm, grade 3-4**                                                                                                        
   ≥ 50                                815          90.9           85.1-94.5   857     96.4   94.0-97.9   0.005      0.387   0.207-0.720   0.003
   ≥ 55                                697          89.8           82.7-94.1   738     96.2   93.6-97.8   0.006      0.388   0.204-0.738   0.004
   ≥ 60                                555          88.1           78.9-93.4   598     95.7   92.5-97.5   0.008      0.391   0.200-0.765   0.006
   ≥ 65                                439          85.3           73.8-92.1   481     94.8   90.9-97.1   0.009      0.392   0.195-0.789   0.009
   ≥ 70                                316          86.1           70.2-93.9   355     94.4   89.6-97.0   0.061      0.440   0.198-0.980   0.044
   ≥ 75                                206          83.4           62.9-93.2   218     94.8   88.4-97.7   0.063      0.343   0.126-0.935   0.037
   ≥ 80                                102          86.5           70.5-94.2   131     94.2   84.8-97.8   0.077      0.337   0.094-1.201   0.093
   ≥ 85                                31           89.3           60.2-97.5   22      NA     NA          0.175      NA      NA            NA
  **Tumor size 11-20 mm, grade 3-4**                                                                                                       
   ≥ 50                                1,806        88.5           85.0-91.2   1,800   93.8   91.4-95.6   \< 0.001   0.524   0.373-0.735   \< 0.001
   ≥ 55                                1,490        87.8           84.7-90.4   1,513   93.9   91.2-95.8   \< 0.001   0.480   0.333-0.693   \< 0.001
   ≥ 60                                1,167        86.7           82.6-89.8   1,191   93.9   91.2-95.8   0.002      0.519   0.348-0.775   0.001
   ≥ 65                                888          85.3           80.2-89.1   915     93.0   89.5-95.4   0.005      0.522   0.336-0.810   0.004
   ≥ 70                                629          83.8           77.3-88.5   663     92.4   87.5-95.4   0.004      0.457   0.276-0.757   0.002
   ≥ 75                                413          81.9           74.2-87.5   423     90.9   82.3-95.4   0.007      0.449   0.247-0.816   0.009
   ≥ 80                                234          77.8           65.1-86.3   268     89.2   70.9-96.3   0.004      0.308   0.137-0.693   0.004
   ≥ 85                                101          70.4           45.0-85.7   60      93.3   61.3-99.0   0.015      0.015   0.001-0.230   0.003

CSS, cancer-specific survival; HR, hormone receptor; PSM, propensity score matching; RT, radiotherapy; CI, confidence interval; aHR, adjusted hazard ratio; NA, not applicable.

Kaplan-Meier survival estimates compared by log-rank test,

Cox proportional hazards model incorporating adjuvant radiotherapy (RT), age, race, year of diagnosis, histology, number of examined lymph nodes, chemotherapy, insurance, and marital status.
